Poniard Pharmaceuticals announced updated efficacy and safety data from its Phase 2 trial of picoplatin in patients with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). This trial evaluated the efficacy and safety of intravenous picoplatin, administered every three weeks in combination with full doses of docetaxel with daily prednisone, as a first-line treatment in 32 patients with metastatic CRPC who have not received prior chemotherapy. Data from the study demonstrated reductions in prostate specific antigen (PSA) levels (primary endpoint), as well as disease control as measured by tumor response and progression-free survival (PFS).
Picoplatin is a new generation platinum-based chemotherapy agent designed to overcome platinum resistance associated with chemotherapy in solid tumors.
For more information call (650) 583-3774 or visit www.poniard.com.